Antisense Therapeutics (ASX: ANP) Webcast Replay
Antisense Therapeutics (ASX: ANP) is an Australian biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases.
As a part of our ‘The Insiders’ series, CEO Mark Diamond provides valuable insights to the company, its key markets and industry, and future prospects.
Recorded on 18 November 2020 at 12pm (AEDT).
Join the next The Insider webcast
FEATURE SPEAKERS
Mark Diamond
Chief Executive Officer - Antisense Therapeutics (ASX: ANP)
Antisense Therapeutics (ASX: ANP) is an Australian biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development
The company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne Muscular Dystrophy (DMD) patients and recently reported highly promising Phase II trial results. While its second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.
